Immune-checkpoint inhibitors in non-small cell lung cancer: A tool to improve patients’ selection
- 1 September 2018
- journal article
- review article
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 129, 27-39
Abstract
No abstract availableKeywords
This publication has 126 references indexed in Scilit:
- Signatures of mutational processes in human cancerNature, 2013
- PD‐1/PDL1 and CD28/CD80 pathways modulate natural killer T cell function to inhibit hepatitis B virus replicationJournal of Viral Hepatitis, 2013
- Maintenance therapy in NSCLC: why? To whom? Which agent?Journal of Experimental & Clinical Cancer Research, 2011
- A single-center, prospective and randomized controlled study: Can the prophylactic use of lamivudine prevent hepatitis B virus reactivation in hepatitis B s-antigen seropositive breast cancer patients during chemotherapy?Breast Cancer Research and Treatment, 2011
- Recent insights in the epidemiology of autoimmune diseases: Improved prevalence estimates and understanding of clustering of diseasesJournal of Autoimmunity, 2009
- CD28− T cells: their role in the age-associated decline of immune functionTrends in Immunology, 2009
- Immunologic Aspects of Chronic Obstructive Pulmonary DiseaseNew England Journal of Medicine, 2009
- Tenofovir Disoproxil Fumarate versus Adefovir Dipivoxil for Chronic Hepatitis BNew England Journal of Medicine, 2008
- A critical function for type I interferons in cancer immunoeditingNature Immunology, 2005
- Defining criteria for autoimmune diseases (Witebsky's postulates revisited)Immunology Today, 1993